{'52WeekChange': 0.05554223,
 'SandP52WeekChange': None,
 'address1': '3891 Ranchero Drive',
 'address2': 'Suite 150',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 40.51,
 'askSize': 1200,
 'averageDailyVolume10Day': 620525,
 'averageVolume': 652314,
 'averageVolume10days': 620525,
 'beta': 2.110364,
 'beta3Year': None,
 'bid': 40.03,
 'bidSize': 900,
 'bookValue': -1.824,
 'category': None,
 'circulatingSupply': None,
 'city': 'Ann Arbor',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 43.74,
 'dayLow': 38.7301,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -4.383,
 'enterpriseToRevenue': 232.79,
 'enterpriseValue': 1113898752,
 'exDividendDate': None,
 'exchange': 'NGM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 47.093143,
 'fiftyTwoWeekHigh': 76.98,
 'fiftyTwoWeekLow': 24.82,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 25089055,
 'forwardEps': -7.22,
 'forwardPE': -5.536011,
 'fromCurrency': None,
 'fullTimeEmployees': 193,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.028619999,
 'heldPercentInstitutions': 1.01109,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': 1370908800,
 'lastSplitFactor': '1:6',
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/esperion.com',
 'longBusinessSummary': 'Esperion Therapeutics, Inc., a lipid management '
                        'company, focuses on developing and commercializing '
                        'oral therapies for the treatment of patients with '
                        'elevated low density lipoprotein cholesterol (LDL-C). '
                        'Its lead product candidate is bempedoic '
                        'acid/ezetimibe combination tablet, a non-statin, '
                        'orally available, LDL-C lowering therapy for patients '
                        'with hypercholesterolemia and with atherosclerotic '
                        'cardiovascular disease, and/or heterozygous familial '
                        'hypercholesterolemia that is in Phase III long-term '
                        'safety and tolerability study. The company has a '
                        'license and collaboration agreement with Daiichi '
                        'Sankyo Europe GmbH. Esperion Therapeutics, Inc. was '
                        'founded in 2008 and is headquartered in Ann Arbor, '
                        'Michigan.',
 'longName': 'Esperion Therapeutics, Inc.',
 'market': 'us_market',
 'marketCap': 1103867520,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_28236',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -262792992,
 'nextFiscalYearEnd': 1640908800,
 'open': 43.74,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -0.31,
 'phone': '734 887 3903',
 'previousClose': 44.09,
 'priceHint': 2,
 'priceToBook': None,
 'priceToSalesTrailing12Months': 230.69331,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 43.74,
 'regularMarketDayLow': 38.7301,
 'regularMarketOpen': 43.74,
 'regularMarketPreviousClose': 44.09,
 'regularMarketPrice': 43.74,
 'regularMarketVolume': 1214602,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 27617400,
 'sharesPercentSharesOut': 0.3667,
 'sharesShort': 10127507,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 8124076,
 'shortName': 'Esperion Therapeutics, Inc.',
 'shortPercentOfFloat': 0.4271,
 'shortRatio': 14.64,
 'startDate': None,
 'state': 'MI',
 'strikePrice': None,
 'symbol': 'ESPR',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -9.64,
 'twoHundredDayAverage': 47.10806,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '00314c6d-38c1-3c8e-a318-bd51d9ba1c8c',
 'volume': 1214602,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.esperion.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '48108'}